Table 1. Clinical, immunophenotypic, and... | Rockefeller University Press

Table 1.

Clinical, immunophenotypic, and molecular characteristics of five normolymphocytic patients with elevated TCR γδ frequencies

FuGe cohort number	44 (P1)		86		528		558		581
Year of birth	1986		1985		1989		1998		1961
Clinical phenotype, associated atopy	Susceptibility to airway infections; oral erosions; elevated IgE		Childhood-onset allergic asthma; recurrent viral-like airway infections; house dust mite desensitization; normal IgE		Recurrent viral-like airway infections (20× per year); tonsillectomy; low IgE		Recurrent tonsillitis and sinusitis since childhood; splenectomy due to spherocytosis; normal IgE		Chronic rhinosinusitis without polyps; asthma; ENT surgery; low IgE
Evaluation date	2017	2025	2019	2024	2023	2024	2024	2024	2024	2025
Neutrophils absolute (G/L); Ref: 1.3–6.7	6.02	4.61	5.94	3.82	6.29	5.43	3.51	N.D	2.87	5.5
Lymphocytes absolute (G/L); Ref: 0.9–3.3	2.39	1.72	3.74	2.51	2.82	2.2	1.91	N.D	2.03	1.99
Lymphocytes (% of leukocytes); Ref: 19–48	26.23	24.20	35.10	35.20	28.40	26.50	30.80	N.D	25.60	24.70
Absolute T cell count (cells/μl); Ref: 742–2,750	1,857	1,317	3,132	2,274	2,629	1,947	1,730	1,792	1,728	1,830
Absolute γδ T cell count (cells/μl)	612	233	1,221	932	565	368	847	914	373	389
γδ T cells (% of total T cells); Ref: 0.5–16	33	17.7	39	41	21.5	18.9	49	51	21.6	21.3
T cell clonality (method)	6.7% (NGS)	13% (NGS)	Biclonal (multiplex PCR)	N.D	7% (NGS)	N.D	N.D	12.7% (NGS)	14% (NGS)	N.D
γδ T-LGL (% of T cells) as assessed by diagnostic hemato-immunologic flow cytometry	25%	12%	42%	N.D	N.D	17%	N.D	40%	25%	N.D
γδ T cell flow phenotype	CD5dim, CD2⁺, CD7⁺, CD52⁺, CD30⁻, CD16⁺, CD56⁺, CD57⁻	CD5dim, CD2⁺, CD7⁺, CD52⁺, CD30⁻, CD16⁺, CD56⁺, CD57⁻	CD5dim, CD2⁺, CD7⁺, CD52⁺, CD30⁻, CD16⁻, CD56⁻, CD57⁺	N.D	N.D	CD5dim, CD2⁺, CD7⁺, CD16⁺, CD56⁺, CD57⁺	N.D	CD5dim, CD2⁺, CD7⁺, CD16⁺, CD56⁺, CD57⁺	CD5dim, CD2⁺, CD7⁺, CD52⁺, CD30⁻, CD16⁺, CD56⁺, CD57⁺	N.D
STAT5B mutation (method)	Yes (NGS-sorted γδ T cells)	N.D	No (NGS-sorted γδ T cells)	N.D	N.D	No (Sanger sequencing; PBMCs)	N.D	No (Sanger sequencing; PBMCs)	No (Sanger sequencing; PBMCs)	N.D
STAT3 mutation (method)	No (NGS-sorted γδ T cells)	N.D	No (NGS-sorted γδ T cells)	N.D	N.D	N.D	N.D	N.D	N.D	N.D
Treatment	Baricitinib		Watch and wait		Watch and wait		Watch and wait		Watch and wait

FuGe cohort number	44 (P1)		86		528		558		581
Year of birth	1986		1985		1989		1998		1961
Clinical phenotype, associated atopy	Susceptibility to airway infections; oral erosions; elevated IgE		Childhood-onset allergic asthma; recurrent viral-like airway infections; house dust mite desensitization; normal IgE		Recurrent viral-like airway infections (20× per year); tonsillectomy; low IgE		Recurrent tonsillitis and sinusitis since childhood; splenectomy due to spherocytosis; normal IgE		Chronic rhinosinusitis without polyps; asthma; ENT surgery; low IgE
Evaluation date	2017	2025	2019	2024	2023	2024	2024	2024	2024	2025
Neutrophils absolute (G/L); Ref: 1.3–6.7	6.02	4.61	5.94	3.82	6.29	5.43	3.51	N.D	2.87	5.5
Lymphocytes absolute (G/L); Ref: 0.9–3.3	2.39	1.72	3.74	2.51	2.82	2.2	1.91	N.D	2.03	1.99
Lymphocytes (% of leukocytes); Ref: 19–48	26.23	24.20	35.10	35.20	28.40	26.50	30.80	N.D	25.60	24.70
Absolute T cell count (cells/μl); Ref: 742–2,750	1,857	1,317	3,132	2,274	2,629	1,947	1,730	1,792	1,728	1,830
Absolute γδ T cell count (cells/μl)	612	233	1,221	932	565	368	847	914	373	389
γδ T cells (% of total T cells); Ref: 0.5–16	33	17.7	39	41	21.5	18.9	49	51	21.6	21.3
T cell clonality (method)	6.7% (NGS)	13% (NGS)	Biclonal (multiplex PCR)	N.D	7% (NGS)	N.D	N.D	12.7% (NGS)	14% (NGS)	N.D
γδ T-LGL (% of T cells) as assessed by diagnostic hemato-immunologic flow cytometry	25%	12%	42%	N.D	N.D	17%	N.D	40%	25%	N.D
γδ T cell flow phenotype	CD5dim, CD2⁺, CD7⁺, CD52⁺, CD30⁻, CD16⁺, CD56⁺, CD57⁻	CD5dim, CD2⁺, CD7⁺, CD52⁺, CD30⁻, CD16⁺, CD56⁺, CD57⁻	CD5dim, CD2⁺, CD7⁺, CD52⁺, CD30⁻, CD16⁻, CD56⁻, CD57⁺	N.D	N.D	CD5dim, CD2⁺, CD7⁺, CD16⁺, CD56⁺, CD57⁺	N.D	CD5dim, CD2⁺, CD7⁺, CD16⁺, CD56⁺, CD57⁺	CD5dim, CD2⁺, CD7⁺, CD52⁺, CD30⁻, CD16⁺, CD56⁺, CD57⁺	N.D
STAT5B mutation (method)	Yes (NGS-sorted γδ T cells)	N.D	No (NGS-sorted γδ T cells)	N.D	N.D	No (Sanger sequencing; PBMCs)	N.D	No (Sanger sequencing; PBMCs)	No (Sanger sequencing; PBMCs)	N.D
STAT3 mutation (method)	No (NGS-sorted γδ T cells)	N.D	No (NGS-sorted γδ T cells)	N.D	N.D	N.D	N.D	N.D	N.D	N.D
Treatment	Baricitinib		Watch and wait		Watch and wait		Watch and wait		Watch and wait

N.D, not done; Ref, reference range. Values above reference range are indicated in bold. Sanger sequencing of bulk PBMC may fail to detect low-variant-allele-frequency mutations in both STAT3 and STAT5B.

[ViewLarge]

Sharing Unavailable